UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Epidemiology and natural history of HCV infection

Nature reviews. Gastroenterology & hepatology, 2013-09, Vol.10 (9), p.553-562

2013

Volltextzugriff (PDF)

Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection

Nature immunology, 2022-02, Vol.23 (2), p.210-216

2022

Volltextzugriff (PDF)

Direct-acting antiviral agents for HCV infection affecting people who inject drugs

Nature reviews. Gastroenterology & hepatology, 2017-11, Vol.14 (11), p.641-651

2017

Volltextzugriff (PDF)

Hepatitis C virus elimination: laying the foundation for achieving 2030 targets

Nature reviews. Gastroenterology & hepatology, 2021-02, Vol.18 (2), p.91-92

2021

Volltextzugriff (PDF)

HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis

Hepatology (Baltimore, Md.), 2022-07, Vol.76 (1), p.139-154

2022

Volltextzugriff (PDF)

Recommandations pour la prise en charge de l’infection par le virus de l’hépatite C chez les usagers de drogues par injection

The International journal of drug policy, 2023-01, Vol.111, p.101669-101669, Article 101669

2023

Volltextzugriff (PDF)

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

Hepatology (Baltimore, Md.), 2016-05, Vol.63 (5), p.1430-1441

2016

Volltextzugriff (PDF)

Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis

Journal of hepatology, 2020-04, Vol.72 (4), p.643-657

2020

Volltextzugriff (PDF)

The changing therapeutic landscape for hepatitis C

Medical journal of Australia, 2012-06, Vol.196 (10), p.629-632

Dore, Gregory J

2012

Volltextzugriff (PDF)

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2014-08, Vol.384 (9941), p.403-413

2014

Volltextzugriff (PDF)

Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression

Hepatology (Baltimore, Md.), 2008-08, Vol.48 (2), p.418-431

2008

Volltextzugriff (PDF)

Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis

The lancet. Gastroenterology & hepatology, 2018-11, Vol.3 (11), p.754-767

2018

Volltextzugriff (PDF)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation

Journal of hepatology, 2016-07, Vol.65 (1), p.17-25

2016

Volltextzugriff (PDF)

Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications

PloS one, 2021-09, Vol.16 (9), p.e0257369

2021

Volltextzugriff (PDF)

Management of acute HCV infection in the era of direct-acting antiviral therapy

Nature reviews. Gastroenterology & hepatology, 2018-07, Vol.15 (7), p.412-424

2018

Volltextzugriff (PDF)

Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy : a meta-analysis

AIDS (London), 2008-10, Vol.22 (15), p.1979-1991

2008

Volltextzugriff (PDF)

Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccines

The Lancet global health, 2022-01, Vol.10 (1), p.e142-e147

2022

Volltextzugriff (PDF)

Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection

PLoS pathogens, 2011-09, Vol.7 (9), p.e1002243-e1002243

2011

Volltextzugriff (PDF)

Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine

The Lancet infectious diseases, 2012-05, Vol.12 (5), p.408-414

2012

Volltextzugriff (PDF)

Mixed HCV infection and reinfection in people who inject drugs--impact on therapy

Nature reviews. Gastroenterology & hepatology, 2015-04, Vol.12 (4), p.218-230

2015

Volltextzugriff (PDF)

Treatment adherence and support for people who inject drugs taking direct‐acting antiviral therapy for hepatitis C infection

Journal of viral hepatitis, 2019-11, Vol.26 (11), p.1301-1310

2019

Volltextzugriff (PDF)

Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries

The Lancet (British edition), 2017-03, Vol.389 (10075), p.1268-1272

2017

Volltextzugriff (PDF)

Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

Nature communications, 2024-04, Vol.15 (1), p.3315-3315, Article 3315

2024

Volltextzugriff (PDF)

Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia

Viruses, 2022-07, Vol.14 (7), p.1496

2022

Volltextzugriff (PDF)

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression

Journal of hepatology, 2017-12, Vol.67 (6), p.1204-1212

2017

Volltextzugriff (PDF)

1 – 25 von 622

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(591)
Mit Volltextzugriff
(555)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(492)
Life Sciences & Biomedicine
(473)
Humans
(391)
Male
(245)
Hepatitis C
(239)
Female
(229)
Infectious Diseases
(219)
Adult
(218)
Gastroenterology & Hepatology
(171)
Hepatitis C Virus
(167)
Middle Aged
(159)
Hepatitis
(145)
Antiviral Agents - Therapeutic Use
(128)
Biological And Medical Sciences
(108)
Medical Sciences
(107)
Immunology
(96)
Hepatitis C - Drug Therapy
(94)
Infections
(94)
Hiv
(93)
Human Immunodeficiency Virus
(93)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Epidemiology and natural history of HCV infection

Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection

Direct-acting antiviral agents for HCV infection affecting people who inject drugs

Hepatitis C virus elimination: laying the foundation for achieving 2030 targets

HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis

Recommandations pour la prise en charge de l’infection par le virus de l’hépatite C chez les usagers de drogues par injection

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis

The changing therapeutic landscape for hepatitis C

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression

Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation

Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications

Management of acute HCV infection in the era of direct-acting antiviral therapy

Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy : a meta-analysis

Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccines

Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection

Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine

Mixed HCV infection and reinfection in people who inject drugs--impact on therapy

Treatment adherence and support for people who inject drugs taking direct‐acting antiviral therapy for hepatitis C infection

Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries

Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression

Suchergebnisse filtern